Netupitant and palonosetron trigger NK1 receptor internalization in NG108-15 cells

Experimental Brain Research

Volumn 232, Issue 8, 2014, Pages 2637-2644

  Thomas, Ajit G ^a   Stathis, Marigo ^a   Rojas, Camilo ^a   Slusher, Barbara S ^a,b  

^a JOHNS HOPKINS UNIVERSITY   (United States)

^b JOHNS HOPKINS UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

Chemotherapy induced nausea and vomiting; Netupitant; Ondansetron; Palonosetron

Indexed keywords

ACID; NETUPITANT; NEUROKININ 1 RECEPTOR; ONDANSETRON; PALONOSETRON; PROTEINASE; SEROTONIN 3 RECEPTOR; ISOQUINOLINE DERIVATIVE; NEUROKININ 1 RECEPTOR ANTAGONIST; PEPTIDE HYDROLASE; PROTEIN BINDING; PYRIDINE DERIVATIVE; QUINUCLIDINE DERIVATIVE; SEROTONIN ANTAGONIST; TRITIUM;

ARTICLE; CANCER PATIENT; CELL MEMBRANE; CHEMOTHERAPY INDUCED NAUSEA AND VOMITING; CONTROLLED STUDY; DISSOCIATION; DRUG EFFICACY; INTERNALIZATION; PRIORITY JOURNAL; PROTEIN EXPRESSION; DRUG HALF LIFE; DRUG POTENTIATION; DRUG PROTEIN BINDING; HEK293 CELL LINE; PROTEIN HYDROLYSIS; ANIMAL; CELL LINE; DOSE RESPONSE; DRUG ADMINISTRATION; DRUG EFFECTS; GENETICS; HUMAN; METABOLISM; MOUSE; NEUROBLASTOMA; PATHOLOGY; PROTEIN TRANSPORT; RAT; TIME;

ACIDS; ANIMALS; CELL LINE; DOSE-RESPONSE RELATIONSHIP, DRUG; DRUG ADMINISTRATION SCHEDULE; HEK293 CELLS; HUMANS; ISOQUINOLINES; MICE; NEUROBLASTOMA; NEUROKININ-1 RECEPTOR ANTAGONISTS; PEPTIDE HYDROLASES; PROTEIN BINDING; PROTEIN TRANSPORT; PYRIDINES; QUINUCLIDINES; RATS; RECEPTORS, NEUROKININ-1; SEROTONIN ANTAGONISTS; TIME FACTORS; TRITIUM;

EID: 84905567561     PISSN: 00144819     EISSN: 14321106     Source Type: Journal    
DOI: 10.1007/s00221-014-4017-7     Document Type: Article

References (27)

1. Aapro MS, Grunberg SM, Manikhas GM, Olivares G, Suarez T, Tjulandin SA, Bertoli LF, Yunus F, Morrica B, Lordick F, Macciocchi A (2006) A phase III, double-blind, randomized trial of palonosetron compared with ondansetron in preventing chemotherapy-induced nausea and vomiting following highly emetogenic chemotherapy. Ann Oncol 17:1441-1449
2. Basch E, Prestrud A, Hesketh PJ, Kris MG, Feyer PC, Somerfield MR, Chesney M, Clark-Snow RA, Flaherty AM, Freundlich B, Morrow G, Rao KV, Schwartz RN, Lyman GH (2011) Antiemetics: American society of clinical oncology clinical practice guideline update. J Clin Oncol 29:4189-4198
3. Darmani NA, Ray AP (2009) Evidence for a re-evaluation of the neurochemical and anatomical bases of chemotherapy-induced vomiting. Chem Rev 109:3158-3199
4. Darmani NA, Crim JL, Janoyan JJ, Abad J, Ramirez J (2009) A reevaluation of the neurotransmitter basis of chemotherapy-induced immediate and delayed vomiting: evidence from the least shrew. Brain Res 1248:40-58
5. Eisenberg P, Figueroa-Vadillo J, Zamora R, Charu V, Hajdenberg J, Cartmell A, Macciocchi A, Grunberg S (2003) Improved prevention of moderately emetogenic chemotherapy-induced nausea and vomiting with palonosetron, a pharmacologically novel 5-HT3 receptor antagonist: results of a phase III, single-dose trial versus dolasetron. Cancer 98:2473-2482
6. Emerit MB, Riad M, Fattaccini CM, Hamon M (1993) Characteristics of [14C] guanidinium accumulation in NG 108-15 cells exposed to serotonin 5-HT3 receptor ligands and substance P. J Neurochem 60:2059-2067
7. Ettinger DS, Armstrong DK, Barbour S, Berger MJPJB, Bradbury B, Ellis G, Kirkegaard S, Kloth DD, Kris MG, Lim D, Boehnke Michaud L, Nabati L, Noonan K, Rugo HS, Siler D, Sorscher SM, Stelts S, Stucky-Marshall L, Todaro B, Urba S (2012) NCN clinical practice guidelines in oncology (NCN Guidelines™) Antiemesis. J Natl Compr Canc Netw 10:456-485
8. Feyer P, Jordan K (2011) Update and new trends in antiemetic therapy: the continuing need for novel therapies. Ann Oncol 22:30-38
9. Gralla R, Lichinitser M, Van Der Vegt S, Sleeboom H, Mezger J, Peschel C, Tonini G, Labianca R, Macciocchi A, Aapro M (2003) Palonosetron improves prevention of chemotherapy-induced nausea and vomiting following moderately emetogenic chemotherapy: results of a double-blind randomized phase III trial comparing single doses of palonosetron with ondansetron. Ann Oncol 14:1570-1577
10. Guetg N, Abdel Aziz S, Holbro N, Turecek R, Rose T, Seddik R, Gassmann M, Moes S, Jenoe P, Oertner TG, Casanova E, Bettler B (2010) NMDA receptor-dependent GABAB receptor internalization via CaMKII phosphorylation of serine 867 in GABAB1. Proc Natl Acad Sci USA 107:13924-13929
11. Haigler HT, Maxfield FR, Willingham MC, Pastan I (1980) Dansylcadaverine inhibits internalization of 125I-epidermal growth factor in BALB 3T3 cells. J Biol Chem 255:1239-1241
12. Hesketh PJ, Van Belle S, Aapro M, Tattersall FD, Naylor RJ, Hargreaves R, Carides AD, Evans JK, Horgan KJ (2003) Differential involvement of neurotransmitters through the time course of cisplatin-induced emesis as revealed by therapy with specific receptor antagonists. Eur J Cancer 39:1074-1080
13. Hu WP, You XH, Guan BC, Ru LQ, Chen JG, Li ZW (2004) Substance P potentiates 5-HT3 receptor-mediated current in rat trigeminal ganglion neurons. Neurosci Lett 365:147-152
14. Lummis SC (2012) 5-HT(3) receptors. J Biol Chem 287:40239-40245
15. Minami M, Endo T, Yokota H, Ogawa T, Nemoto M, Hamaue N, Hirafuji M, Yoshioka M, Nagahisa A, Andrews PL (2001) Effects of CP-99, 994, a tachykinin NK(1) receptor antagonist, on abdominal afferent vagal activity in ferrets: evidence for involvement of NK(1) and 5-HT(3) receptors. Eur J Pharmacol 428:215-220
16. Reiser G, Hamprecht B (1989) Substance P and serotonin act synergistically to activate a cation permeability in a neuronal cell line. Brain Res 479:40-48
17. Rizzi A, Campi B, Camarda V, Molinari S, Cantoreggi S, Regoli D, Pietra C, Calo G (2012) In vitro and in vivo pharmacological characterization of the novel NK(1) receptor selective antagonist netupitant. Peptides 37:86-97
18. Roila F, Herrstedt J, Aapro M, Gralla RJ, Einhorn LH, Ballatori E, Bria E, Clark-Snow RA, Espersen BT, Feyer P, Grunberg SM, Hesketh PJ, Jordan K, Kris MG, Maranzano E, Molassiotis A, Morrow G, Olver I, Rapoport BL, Rittenberg C, Saito M, Tonato M, Warr D (2010) Guideline update for MASC and ESMO in the prevention of chemotherapy- and radiotherapy-induced nausea and vomiting: results of the Perugia consensus conference. Ann Oncol 21(Suppl 5):v232-v243
19. Rojas C, Stathis M, Thomas AG, Massuda EB, Alt J, Zhang J, Rubenstein E, Sebastiani S, Cantoreggi S, Snyder SH, Slusher B (2008) Palonosetron exhibits unique molecular interactions with the 5-HT3 receptor. Anesth Analg 107:469-478
20. Rojas C, Li Y, Zhang J, Stathis M, Alt J, Thomas AG, Cantoreggi S, Sebastiani S, Pietra C, Slusher BS (2010a) The antiemetic 5-HT3 receptor antagonist palonosetron inhibits substance P-mediated responses in vitro and in vivo. J Pharmacol Exp Ther 335:362-368
21. Rojas C, Thomas AG, Alt J, Stathis M, Zhang J, Rubenstein EB, Sebastiani S, Cantoreggi S, Slusher BS (2010b) Palonosetron triggers 5-HT(3) receptor internalization and causes prolonged inhibition of receptor function. Eur J Pharmacol 626:193-199
22. Rojas C, Raje M, Tsukamoto T, Slusher BS (2014) Molecular mechanisms of 5-HT3 and NK1 receptor antagonists in prevention of emesis. Eur J Pharmacol 722:26-37
23. Saito M, Aogi K, Sekine I, Yoshizawa H, Yanagita Y, Sakai H, Inoue K, Kitagawa C, Ogura T, Mitsuhashi S (2009) Palonosetron plus dexamethasone versus granisetron plus dexamethasone for prevention of nausea and vomiting during chemotherapy: a doubleblind, double-dummy, randomised, comparative phase III trial. Lancet Oncol 10:115-124
24. Simantov R, Sachs L (1973) Regulation of acetylcholine receptors in relation to acetylcholinesterase in neuroblastoma cells. Proc Natl Acad Sci USA 70:2902-2905
25. Stathis M, Pietra C, Rojas C, Slusher B (2012) Inhibition of substance P-mediated responses in NG108-15 cells by netupitant and palonosetron exhibit synergistic effects. Eur J Pharmacol 689:25-30
26. Tattersall FD, Rycroft W, Cumberbatch M, Mason G, Tye S, Williamson DJ, Hale JJ, Mills SG, Finke PE, MacCoss M, Sadowski S, Ber E, Cascieri M, Hill RG, MacIntyre DE, Hargreaves RJ (2000) The novel NK1 receptor antagonist MK-0869 (L-754,030) and its water soluble phosphoryl prodrug, L758,298, inhibit acute and delayed cisplatin-induced emesis in ferrets. Neuropharmacology 39:652-663
27. Wong EH, Clark R, Leung E, Loury D, Bonhaus DW, Jakeman L, Parnes H, Whiting RL, Eglen RM (1995) The interaction of RS 25259-197, a potent and selective antagonist, with 5-HT3 receptors, in vitro. Br J Pharmacol 114:851-859